Abstract

BackgroundThe order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR patients show comparable efficacy results across...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
THU0034 Use of Rituximab Compared To Anti-Tnf Agents as Second and Third-Line Therapy in Patients with Rheumatoid Arthritis. A 6-Year Follow-Up Report from The Rhumadata® Clinical Database and Registry
J.-P Pelletier ... L Coupal
Annals of the Rheumatic Diseases | VOL. 75
J.-P Pelletier, et. al.J.-P Pelletier ... L Coupal
01 Jun 2016
THU0035 Six Years Tocilizumab Use in Patients with Rheumatoid Arthritis with One Previous anti-TNF Agent Exposure: Comparison with Adalimumab and Etanercept from The Provincial Electronic Database and Registry Rhumadata®
J.-P Pelletier ... F Massicotte
Annals of the Rheumatic Diseases | VOL. 75
J.-P Pelletier, et. al.J.-P Pelletier ... F Massicotte
01 Jun 2016
Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis.
Hiroshi Watanabe ... Makiko Yashiro-Furuya
Medicina (Kaunas, Lithuania) | VOL. 57
Hiroshi Watanabe, et. al.Hiroshi Watanabe ... Makiko Yashiro-Furuya
31 Aug 2021
SAT0104 Comparison of Drug Discontinuation to Inefficacy and Adverse Events Between Anti-Tnf Agents and ‘Non-Anti-Tnf Biologic Agents’ in Anti-Tnf Inadequate Responder Rheumatoid Arthritis Patients
...
Annals of the Rheumatic Diseases | VOL. 72
, et. al. ...
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers